Other FDA Approved

Anidulafungin

A semisynthetic echinocandin lipopeptide antifungal that inhibits fungal 1,3-beta-D-glucan synthase, FDA approved on February 17, 2006 as Eraxis for candidemia, intra-abdominal Candida infections and esophageal candidiasis, with the pediatric indication extended to infants 1 month and older in 2020.

AntifungalEchinocandinLipopeptideGlucan SynthaseFDA Approved

Also referenced as: LY303366, LY-303366, Eraxis, Ecalta

Also appears in: Immune

Public product evidence No certificate records are bound to a tracked Anidulafungin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Anidulafungin product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Other research areas

Primary research area: Other. Also surfaces under Immune for browsing and discovery.

Body systems
Immune · Systemic

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
4

LY303366, LY-303366, Eraxis, Ecalta

Signal depth
Medium

FDA label signal · 48 trials · 1389 PubMed results

Established

Anidulafungin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Anidulafungin has 33 name-matched clinical trials (highest phase: Phase 4) and 1389 PubMed-indexed publications and holds an FDA drug label. 16 trials have posted results.

FAERS (approved drug): 1,459
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Anidulafungin?

Anidulafungin is a semisynthetic lipopeptide antifungal of the echinocandin class, the same family as caspofungin, micafungin and rezafungin. The US label describes it as a semi-synthetic lipopeptide synthesized from a fermentation product of the fungus Aspergillus nidulans: a cyclic hexapeptide core of echinocandin B carrying, in place of the natural fatty-acid tail, a pentyloxy-terphenyl side chain. The empirical formula is C58H73N7O17 and the formula weight 1,140.3. It is not a hormone or signaling peptide; its target is an enzyme found in fungal cell walls and absent from mammalian cells.

The compound was studied preclinically under the Eli Lilly code LY303366, with concentration-dependent fungicidal activity shown in neutropenic rabbits (Petraitiene et al., Antimicrobial Agents and Chemotherapy, 1999;43(9):2148–2155). Its clinical development was run by Vicuron Pharmaceuticals, and it reached the US market through Vicuron Holdings, a Pfizer subsidiary, as Eraxis; the same product is sold as Ecalta in the European Union. It was the third echinocandin approved in the US after caspofungin and micafungin, and its distinguishing feature is pharmacokinetic rather than microbiological: the molecule is cleared by slow chemical degradation instead of hepatic metabolism, so exposure does not change with liver or kidney function. It is a hospital antifungal with essentially no footprint in the research-peptide market.

How it works

  • Inhibition of 1,3-beta-D-glucan synthase. The label states that anidulafungin inhibits glucan synthase, an enzyme present in fungal but not mammalian cells, and so blocks formation of 1,3-beta-D-glucan, an essential component of the fungal cell wall. Cryo-EM structures of the yeast catalytic subunit Fks1 place the active site at the membrane-cytoplasm interface and cluster echinocandin-resistance mutations near transmembrane helices 5, 6 and 8 (Hu et al., Nature, 2023;616(7955):190–198), and structures with bound caspofungin show the echinocandin forming a ternary complex with nascent glucan that stalls polymer translocation, a mechanism shared across the class (Ren et al., Nature, 2026;654(8118):547–555).
  • Spectrum against Candida and Aspergillus. The label lists activity in vitro and in clinical infections against Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis, and the early clinical review noted potent in vitro activity against Aspergillus and Candida species, including isolates resistant to fluconazole or amphotericin B (Vazquez and Sobel, Clinical Infectious Diseases, 2006;43(2):215–222); the approved indications are limited to Candida infections.
  • Elimination by chemical degradation, not metabolism. According to the label, anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to an inactive ring-opened peptide, with an in vitro degradation half-life of about 24 hours; it is not metabolized by cytochrome P450 or by human hepatocytes, is more than 99% protein bound, and has a terminal elimination half-life of 40 to 50 hours. A population analysis of 600 plasma samples from 225 patients found that weight and sex explained less than 20% of between-patient variability in clearance and that rifampin and cytochrome P450 modulators did not alter it (Dowell et al., Journal of Clinical Pharmacology, 2004;44(6):590–598). A phase 1 program found no dosage adjustment needed in hepatic or renal impairment (Dowell et al., Journal of Clinical Pharmacology, 2007;47(4):461–470), and no clinically relevant interaction was seen with cyclosporine (Dowell et al., Journal of Clinical Pharmacology, 2005;45(2):227–233).
  • Resistance through FKS hot-spot mutations. The label attributes reduced susceptibility to point mutations in the FKS1 and FKS2 genes encoding glucan synthase subunits. Resistance in susceptible species is acquired during therapy through amino acid changes in hot-spot regions of the Fks subunits, with Candida glabrata most often affected (Perlin, Annals of the New York Academy of Sciences, 2015;1354(1):1–11). In 293 episodes of Candida glabrata bloodstream infection at one US center between 2001 and 2010, echinocandin resistance rose from 4.9% to 12.3%, prior echinocandin therapy predicted FKS mutants with an odds ratio of 19.6, and 8 of 10 patients infected with such mutants failed echinocandin treatment or relapsed (Alexander et al., Clinical Infectious Diseases, 2013;56(12):1724–1732).

Research status

Phase 2 dose-ranging. A randomized study of 123 patients with invasive candidiasis or candidemia compared 50, 75 and 100 mg once daily; global success at the end of therapy was 84%, 90% and 89% in the 68 evaluable patients, with no dose-related safety signal (Krause et al., Antimicrobial Agents and Chemotherapy, 2004;48(6):2021–2024).

Esophageal candidiasis phase 3. A double-blind, double-dummy trial in 601 patients with documented esophageal candidiasis compared intravenous anidulafungin with oral fluconazole. Endoscopic success at the end of therapy was 97.2% (242 of 249) versus 98.8% (252 of 255), a difference of −1.6% (95% CI −4.1 to 0.8) that met the noninferiority criterion; treatment-related adverse events occurred in 9.3% and 12.0% (Krause et al., Clinical Infectious Diseases, 2004;39(6):770–775). The US label adds that two weeks after therapy, endoscopically documented relapse was 53.3% (120 of 225) with anidulafungin versus 19.3% (45 of 233) with fluconazole.

Pivotal invasive candidiasis trial (NCT00056368). The Pfizer-sponsored, double-blind phase 3 trial ran from March 2003 to October 2004 and enrolled 256 adults, randomized to intravenous anidulafungin or intravenous fluconazole with optional oral fluconazole after 10 days. In the 245-patient primary analysis, 89% had candidemia only, 62% had Candida albicans and 97% were not neutropenic. Global response at the end of intravenous therapy was successful in 75.6% versus 60.2%, a difference of 15.4 percentage points (95% CI 3.9 to 27.0) that met the noninferiority margin and reached statistical superiority; with the largest-enrolling site removed, the rates were 73.2% versus 61.1% (difference 12.1 points, 95% CI −1.1 to 25.3). All-cause mortality was 23% versus 31% (P = 0.13), and adverse events were similar (Reboli et al., New England Journal of Medicine, 2007;356(24):2472–2482). A post hoc analysis of the 163 participants who met criteria for critical illness found global response of 70.8% versus 54.1% (P = 0.03) and 14-day mortality of 10.1% versus 20.3% (P = 0.08) (Kett et al., Critical Care, 2011;15(5):R253).

Post-approval adult studies. A phase 4 open-label trial (NCT00496197) enrolled 282 patients with candidemia or invasive candidiasis and allowed step-down from intravenous anidulafungin to oral fluconazole or voriconazole after 5 days; the global response rate at the end of treatment in the 250-patient modified intention-to-treat population was 83.7% (95% CI 78.7 to 88.8) (Vazquez et al., BMC Infectious Diseases, 2014;14:97). A randomized comparison with caspofungin in neutropenic patients (NCT00806351) was terminated on May 18, 2012 for slow enrollment after 21 participants.

Invasive aspergillosis combination trial (NCT00531479). A double-blind trial at 93 sites randomized 454 patients with hematologic malignancy or hematopoietic cell transplantation and invasive aspergillosis to voriconazole plus anidulafungin or voriconazole plus placebo. In the 277 patients with confirmed disease, 6-week mortality was 19.3% with the combination and 27.5% with monotherapy, a difference of −8.2 percentage points (95% CI −19.0 to 1.5; P = 0.087) that missed the primary endpoint (Marr et al., Annals of Internal Medicine, 2015;162(2):81–89). No aspergillosis indication followed.

Pediatric program. After a weight-based pharmacokinetic study in neutropenic children aged 2 to 17 (Benjamin et al., Antimicrobial Agents and Chemotherapy, 2006;50(2):632–638), the open-label phase 3 study A8851008 (NCT00761267), run by Pfizer from February 2009 to February 2018 in 70 children, reported in two parts. Among 49 children aged 2 to under 18 years, global response at the end of intravenous therapy was 70.8%, all-cause mortality by week 6 was 14.3% with no death judged treatment related, and 5 discontinued for adverse events (Roilides et al., Pediatric Infectious Disease Journal, 2019;38(3):275–279). Among 19 patients aged 1 month to under 2 years, the success rate was 68.8% and pharmacokinetics matched adults (Roilides et al., Pediatric Infectious Disease Journal, 2020;39(4):305–309). On September 22, 2020 the FDA approved supplement S-027, adding patients 1 month of age and older to the candidemia and intra-abdominal infection indication and fulfilling a deferred pediatric postmarketing requirement from the 2006 approval letter, together with labeling supplement S-029. Health Canada authorized the same pediatric extension on May 8, 2023, restricted to non-neutropenic children, noting aminotransferase elevations in 7 to 10% of pediatric subjects against 2% of adults.

Regulatory path. The FDA approved Eraxis on February 17, 2006 under NDA 021632 (Vicuron Holdings) and the parallel NDA 021948 (Pfizer) as a standard-review new molecular entity for candidemia, other Candida infections and esophageal candidiasis. The European Commission authorized Ecalta on September 20, 2007 for invasive candidiasis in adults, later extended to patients aged 1 month and older, and Health Canada issued a Notice of Compliance for Eraxis on November 14, 2007 for non-neutropenic adults. As of November 2026, Drugs@FDA lists no approved generic anidulafungin application.

Common dosage forms

  • Eraxis for injection. Single-dose vials of lyophilized anidulafungin powder in 50 mg and 100 mg strengths for intravenous infusion, administered by hospital clinicians; the only marketed US presentation.
  • Ecalta and Canadian Eraxis. The same lyophilized powder for intravenous infusion, supplied in the European Union as Ecalta and in Canada as Eraxis in a 100 mg vial.
  • No other presentation. No oral, topical or inhaled anidulafungin product exists.

Key considerations

  • Regulatory status. The FDA Approved status reflects the February 17, 2006 approval of Eraxis (anidulafungin) for injection under NDA 021632 for candidemia and other Candida infections and for esophageal candidiasis. The indication was extended to patients 1 month of age and older on September 22, 2020, the European Union authorized Ecalta on September 20, 2007, and Health Canada approved Eraxis on November 14, 2007.
  • Strong candidemia data with stated limits. The pivotal trial was designed for noninferiority to fluconazole and showed a 15.4-point advantage, but the confidence interval crossed zero once the largest site was excluded, and the population was 97% non-neutropenic. The label says the drug has not been studied in Candida endocarditis, osteomyelitis or meningitis, or in enough neutropenic patients.
  • Esophageal candidiasis relapses. Endoscopic cure matched oral fluconazole at the end of treatment, yet relapse two weeks later was 53.3% versus 19.3%, and the label carries a statement that the drug is associated with high relapse rates in this indication.
  • Safety signals to weigh. Hepatic enzyme abnormalities and infusion reactions were the main signals in the trials. In a repeat-dose rat study anidulafungin produced transaminase elevations, hepatocyte necrosis and hematologic changes attributed to reactive intermediates from its chemical lability, the weakness that rezafungin was designed to remove (Ong et al., Antimicrobial Agents and Chemotherapy, 2016;60(11):6872–6879).
  • A lipopeptide, and not an alias of its siblings. Anidulafungin, LY303366, Eraxis and Ecalta denote one molecule. Caspofungin, micafungin and rezafungin are separate echinocandins with their own approvals that share the FKS-mediated resistance pattern.